Do Wall Street Analysts Like Eli Lilly Stock?

With a market cap of $931.3 billion, Eli Lilly and Company (LLY) discovers, develops, manufactures, and markets medicines across major regions including the United States, Europe, China, and Japan. Its portfolio spans treatments for diabetes, cancer, immunological conditions, neurological disorders, and obesity, supported by strategic collaborations with companies like Boehringer Ingelheim and F. Hoffmann-La Roche.

Shares of the pharmaceutical giant have slightly lagged behind the broader market over the past 52 weeks. LLY stock has increased 28.2% over this time frame, while the broader S&P 500 Index ($SPX) has gained 30.6%. In addition, the stock has declined 7.5% on a YTD basis, compared to SPX's 7% gain.